The characteristics of tuberculosis (TB) patients related to a chain of recent TB transmissions were investigated. Mycobacterium tuberculosis (MTB) isolates (120) were genotyped using the restriction fragment length polymorphism-IS6110 (R), spacer oligotyping (S) and mycobacterial interspersed repetitive units-variable number of tandem repeats (M) methods. The MTB isolates were clustered and the clusters were grouped according to the similarities of their genotypes. Spearman’s rank correlation coefficients between the groups of MTB isolates with similar genotypes and those patient characteristics indicating a risk for a pulmonary TB (PTB) chain transmission were ana- lysed. The isolates showing similar genotypes were distributed as follows: SMR (5%), SM (12.5%), SR (1.67%), MR (0%), S (46.67%), M (5%) and R (0%). The remaining 35 cases were orphans. SMR exhibited a significant correlation (p < 0.05) with visits to clinics, municipalities and comorbidities (primarily diabetes mellitus). S correlated with drug consumption and M with comorbidities. SMR is needed to identify a social network in metropolitan areas for PTB transmission and S and M are able to detect risk factors as secondary components of a transmission chain of TB.

The resistance of 139 Mycobacterium tuberculosis (MTB) isolates from the city of Monterrey, Northeast Mexico, to first and second-line anti-TB drugs was analysed. A total of 73 isolates were susceptible and 66 were resistant to anti-TB drugs. Monoresistance to streptomycin, isoniazid (INH) and ethambutol was observed in 29 cases. Resistance to INH was found in 52 cases and in 29 cases INH resistance was combined with resistance to two or three drugs. A total of 24 isolates were multidrug-resistant (MDR) resistant to at least INH and rifampicin and 11 MDR cases were resistant to five drugs. The proportion of MDR-TB among new TB cases in our target population was 0.72% (1/139 cases). The proportion of MDR-TB among previously treated cases was 25.18% (35/139 cases). The 13 polyresistant and 24 MDR isolates were assayed against the following seven second-line drugs: amikacin (AMK), kanamycin (KAN), capreomycin (CAP), clofazimine (CLF), ethionamide (ETH), ofloxacin (OFL) and cycloserine (CLS). Resistance to CLF, OFL or CLS was not observed. Resistance was detected to ETH (10.80%) and to AMK (2.70%), KAN (2.70%) and CAP (2.70%). One isolate of MDR with primary resistance was also resistant to three second-line drugs. Monterrey has a high prevalence of MDR-TB among previously treated cases and extensively drug-resistant-MTB strains may soon appear.

The quantification of colony forming units (cfu), turbidity, and optical density at 600 nm (OD600) measurements were used to evaluate Mycobacterium tuberculosis growth. Turbidity and OD600 measurements displayed similar growth curves, while cfu quantification showed a continuous growth curve. We determined the cfu equivalents to McFarland and OD600 units.

Tuberculosis (TB - Mycobacterium tuberculosis) is an ancient infectious disease that has appeared once again as a serious worldwide health problem and now comprises the second leading cause of death resulting from a single infection. The prevalence of multidrug resistance (MDR) TB is increasing and therapeutic options for treatment are not always accessible; in fact, some patients do not respond to the available drugs. Therefore, there is an urgent need to develop novel anti-TB agents. The aim of the present study was to screen extracts of Aristolochia taliscana, a plant used in traditional Mexican medicine to treat cough and snake bites, for antimycobacterial activity. The hexanic extract of A. taliscana was tested by microdilution alamar blue assay against Mycobacterium strains and bioguided fractionation led to the isolation of the neolignans licarin A, licarin B and eupomatenoid-7, all of which had antimycobacterial activity. Licarin A was the most active compound, with minimum inhibitory concentrations of 3.12-12.5 μg/mL against the following M. tuberculosis strains: H37Rv, four mono-resistant H37Rv variants and 12 clinical MDR isolates, as well as against five non-tuberculous mycobacteria (NTM) strains. In conclusion, licarin A represents a potentially active anti-TB agent to treat MDR M. tuberculosis and NTM strains.

The results on the bioevaluation of thirty five plant-derived secondary metabolites against one sensitive and three multidrug-resistant clinical isolates of Mycobacterium tuberculosis are reported. Results toward the sensitive strain showed that five products gave MIC values of 12.5 µg/mL: the alkaloids 6-methoxydihydrochelerytrine (2) and 6-methoxy-dihydrochelirubine (6), the flavanone pinostrobin (17), 1-hydroxy-benzoisochromanquinone (23) and 23-hydroxy-5a-lanosta-7,9(11),24-triene-3-one (33). These were followed by the peracetylstrictosidine lactam (12) and the quinone aloe-emodin (24) which displayed MICs of 6.25 µg/mL. Finally, liriodenine (8) was the most active (MIC: 3.125 µg/mL) of all secondary metabolites. Results with the multidrug-resistant clinical isolates showed that 6-methoxy-dihydrochelirubine (6) was the most active (MIC: 12.5 µg/mL).

Se informan los resultados sobre la bioevaluación de treinta y cinco metabolitos secundarios de plantas frente a una cepa sensible y a tres cepas resistentes a múltiples drogas de Mycobacterium tuberculosis. Los resultados frente a la cepa sensible mostraron que cinco metabolitos secundarios poseen valores de CMI de 12.5 µg/mL: los alcaloides 6-metoxidihidroqueleritrina (2) y 6-metoxi-dihidroque-lirubina (6), la flavanona pinostrobina (17), 1-hidroxi-benzoisocromanquinona (23) y el triterpeno 23-hidroxi-5a-lanosta-7,9(11),24-trien-3-ona (33). La lactama de peracetilestrictosidina (12) y la quinona aloe-emodina (24) mostraron CMIs de 6.25 µg/mL. Finalmente, liriodenina (8) fue la substancia mas activa (CMI: 3.125 µg/mL) de todos los metabolitos secundarios. Los resultados con los aislados clínicos resistentes a multidrogas mostraron que 6-metoxi-dihidroquelirubina (6) fue el compuesto mas activo (CMI: 12.5 µg/mL).